Published in J Mol Biol on February 13, 2010
Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J Virol (2011) 1.58
HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism. Nat Struct Mol Biol (2012) 1.52
HIV-1 reverse transcription. Cold Spring Harb Perspect Med (2012) 1.29
Complexes of HIV-1 RT, NNRTI and RNA/DNA hybrid reveal a structure compatible with RNA degradation. Nat Struct Mol Biol (2013) 1.25
Structural factors that determine selectivity of a high fidelity DNA polymerase for deoxy-, dideoxy-, and ribonucleotides. J Biol Chem (2012) 1.11
Structural and inhibition studies of the RNase H function of xenotropic murine leukemia virus-related virus reverse transcriptase. Antimicrob Agents Chemother (2012) 1.01
HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug. Antimicrob Agents Chemother (2012) 0.91
Identification and characterization of a novel HIV-1 nucleotide-competing reverse transcriptase inhibitor series. Antimicrob Agents Chemother (2013) 0.90
Structures of HIV-1 RT-RNA/DNA ternary complexes with dATP and nevirapine reveal conformational flexibility of RNA/DNA: insights into requirements for RNase H cleavage. Nucleic Acids Res (2014) 0.88
4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms. J Biol Chem (2014) 0.87
Structural requirements for RNA degradation by HIV-1 reverse transcriptase. Nat Struct Mol Biol (2013) 0.87
Mutation V111I in HIV-2 reverse transcriptase increases the fitness of the nucleoside analogue-resistant K65R and Q151M viruses. J Virol (2014) 0.78
Protein-mediated antagonism between HIV reverse transcriptase ligands nevirapine and MgATP. Biophys J (2013) 0.77
Reply to "Structural requirements for RNA degradation by HIV-1 reverse transcriptase". Nat Struct Mol Biol (2013) 0.77
Mechanism of resistance to GS-9148 conferred by the Q151L mutation in HIV-1 reverse transcriptase. Antimicrob Agents Chemother (2011) 0.76
A mechanistic and structural investigation of modified derivatives of the diaryltriazine class of NNRTIs targeting HIV-1 reverse transcriptase. Biochim Biophys Acta (2014) 0.76
Structural Maturation of HIV-1 Reverse Transcriptase-A Metamorphic Solution to Genomic Instability. Viruses (2016) 0.75
Herb-target interaction network analysis helps to disclose molecular mechanism of traditional Chinese medicine. Sci Rep (2016) 0.75
Insight into HIV-1 reverse transcriptase-aptamer interaction from molecular dynamics simulations. J Mol Model (2014) 0.75
Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature (2005) 23.04
Evolution of genes and genomes on the Drosophila phylogeny. Nature (2007) 18.01
Structural genomics: beyond the human genome project. Nat Genet (1999) 5.58
Conformational and helicoidal analysis of 30 PS of molecular dynamics on the d(CGCGAATTCGCG) double helix: "curves", dials and windows. J Biomol Struct Dyn (1989) 3.78
PHASES-95: a program package for processing and analyzing diffraction data from macromolecules. Methods Enzymol (1997) 3.74
Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc (1997) 3.69
Hybrid DNA virus in Chinese patients with seronegative hepatitis discovered by deep sequencing. Proc Natl Acad Sci U S A (2013) 3.35
Resident dendritic cells are the predominant TNF-secreting cell in early renal ischemia-reperfusion injury. Kidney Int (2007) 2.98
The Doa4 deubiquitinating enzyme is functionally linked to the vacuolar protein-sorting and endocytic pathways. Mol Biol Cell (2000) 2.94
Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors. Nature (2003) 2.81
Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother (2002) 2.71
A novel repression module, an extensive activation domain, and a bipartite nuclear localization signal defined in the immediate-early transcription factor Egr-1. Mol Cell Biol (1993) 2.61
Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother (2006) 2.41
Selection of single blastocysts for fresh transfer via standard morphology assessment alone and with array CGH for good prognosis IVF patients: results from a randomized pilot study. Mol Cytogenet (2012) 2.39
Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med (2014) 2.07
A DNA aptamer which binds to and inhibits thrombin exhibits a new structural motif for DNA. Biochemistry (1993) 2.07
In vivo disassembly of free polyubiquitin chains by yeast Ubp14 modulates rates of protein degradation by the proteasome. EMBO J (1997) 2.03
Vancomycin-associated drug reaction with eosinophilia and systemic symptoms syndrome. Intern Med J (2014) 2.00
Hyperhomocysteinaemia, Helicobacter pylori, and coronary heart disease. Heart (1997) 1.99
DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage. Nature (2006) 1.81
Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother (2008) 1.79
Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother (2006) 1.79
Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir. Nat Struct Mol Biol (2004) 1.78
Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Res (2009) 1.77
Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell Host Microbe (2011) 1.74
Crystal structure of the thiamin diphosphate-dependent enzyme pyruvate decarboxylase from the yeast Saccharomyces cerevisiae at 2.3 A resolution. J Mol Biol (1996) 1.74
A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr (2013) 1.68
Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J Biol Chem (2003) 1.66
Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother (2005) 1.63
Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology (2010) 1.63
Domain communication in the dynamical structure of human immunodeficiency virus 1 protease. Proc Natl Acad Sci U S A (1990) 1.61
In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. Antivir Ther (2006) 1.60
How stigmatizing is stigma in the life of people living with HIV: a study on HIV positive individuals from Chennai, South India. AIDS Care (2005) 1.57
In vivo incorporation of unnatural amino acids to probe structure, dynamics, and ligand binding in a large protein by nuclear magnetic resonance spectroscopy. J Am Chem Soc (2008) 1.57
Crystal structure of outer surface protein C (OspC) from the Lyme disease spirochete, Borrelia burgdorferi. EMBO J (2001) 1.54
New class of HIV-1 integrase (IN) inhibitors with a dual mode of action. J Biol Chem (2012) 1.52
Current status and challenges of antiretroviral research and therapy. Antiviral Res (2009) 1.52
Time dependence of atomic fluctuations in proteins: analysis of local and collective motions in bovine pancreatic trypsin inhibitor. Biochemistry (1982) 1.48
The Epstein-Barr virus nuclear protein SM is both a post-transcriptional inhibitor and activator of gene expression. Proc Natl Acad Sci U S A (1998) 1.47
Contact screening and chemoprophylaxis in India's Revised Tuberculosis Control Programme: a situational analysis. Int J Tuberc Lung Dis (2009) 1.44
The yeast SEN3 gene encodes a regulatory subunit of the 26S proteasome complex required for ubiquitin-dependent protein degradation in vivo. Mol Cell Biol (1995) 1.43
Morphologic and body composition changes are different in men and women on generic combination antiretroviral therapy--an observational study. J Assoc Physicians India (2010) 1.43
Structural genomics of protein phosphatases. J Struct Funct Genomics (2007) 1.40
Visualizing ATP-dependent RNA translocation by the NS3 helicase from HCV. J Mol Biol (2010) 1.38
Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors. J Virol (2011) 1.38
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother (2007) 1.37
The 2B domain of the Escherichia coli Rep protein is not required for DNA helicase activity. Proc Natl Acad Sci U S A (2002) 1.37
Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance. J Biol Chem (2009) 1.37
The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos (2002) 1.36
p300/cAMP-responsive element-binding protein interactions with ets-1 and ets-2 in the transcriptional activation of the human stromelysin promoter. J Biol Chem (1999) 1.34
Global aspects of tuberculosis in children. Paediatr Respir Rev (2001) 1.33
The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness. J Acquir Immune Defic Syndr (2012) 1.32
Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment. Mol Psychiatry (2013) 1.30
Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors. J Mol Biol (2008) 1.30
Non-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cells. PLoS One (2013) 1.29
Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein. J Virol (2003) 1.28
Association with the cellular export receptor CRM 1 mediates function and intracellular localization of Epstein-Barr virus SM protein, a regulator of gene expression. J Virol (1999) 1.28
Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys. Mol Pharm (2009) 1.28
The tertiary structure of a DNA aptamer which binds to and inhibits thrombin determines activity. Biochemistry (1993) 1.27
Understanding PRRSV infection in porcine lung based on genome-wide transcriptome response identified by deep sequencing. PLoS One (2010) 1.27
Defining the role of phosphomethylethanolamine N-methyltransferase from Caenorhabditis elegans in phosphocholine biosynthesis by biochemical and kinetic analysis. Biochemistry (2006) 1.26
Prevalence of respiratory diseases and their association with growth rate and space in randomly selected swine herds. Can J Vet Res (1986) 1.25
The human herpesvirus 8 homolog of Epstein-Barr virus SM protein (KS-SM) is a posttranscriptional activator of gene expression. J Virol (2000) 1.24
RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information. J Med Chem (2009) 1.24
Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. J Med Chem (2010) 1.22
A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr (2014) 1.22
Catalytic centers in the thiamin diphosphate dependent enzyme pyruvate decarboxylase at 2.4-A resolution. Biochemistry (1993) 1.21
The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations. Antivir Ther (2006) 1.21
Abrogation of a mitotic checkpoint by E2 proteins from oncogenic human papillomaviruses correlates with increased turnover of the p53 tumor suppressor protein. EMBO J (1997) 1.20
The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation. J Acquir Immune Defic Syndr (2008) 1.19
Alcohol use and HIV sexual risk among MSM in Chennai, India. Int J STD AIDS (2011) 1.19
Comparative analyses by sequencing of transcriptomes during skeletal muscle development between pig breeds differing in muscle growth rate and fatness. PLoS One (2011) 1.19
Epstein-Barr virus SM protein interacts with mRNA in vivo and mediates a gene-specific increase in cytoplasmic mRNA. J Virol (2001) 1.18
A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT. AIDS (2005) 1.17
Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrob Agents Chemother (2013) 1.17
Molecular genetic analysis of Epstein-Barr virus Cp promoter function. J Virol (1996) 1.16
Structural and binding analysis of pyrimidinol carboxylic acid and N-hydroxy quinazolinedione HIV-1 RNase H inhibitors. Antimicrob Agents Chemother (2011) 1.16
Novel targets for HIV therapy. Antiviral Res (2008) 1.15
Structure of the receptor binding fragment HC of tetanus neurotoxin. Nat Struct Biol (1997) 1.14
Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir Ther (2007) 1.14
Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131. Antimicrob Agents Chemother (2006) 1.14
In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. Antimicrob Agents Chemother (2006) 1.14
Binding of the adenovirus VAI RNA to the interferon-induced 68-kDa protein kinase correlates with function. Proc Natl Acad Sci U S A (1991) 1.13
Seroprevalence of human immunodeficiency virus (HIV) infection among tuberculosis patients in Tamil Nadu. Indian J Med Res (2003) 1.12
Development of a dissolution medium for nimodipine tablets based on bioavailability evaluation. Eur J Pharm Sci (2004) 1.12
Metabolic activation of the anti-hepatitis C virus nucleotide prodrug PSI-352938. Antimicrob Agents Chemother (2012) 1.12
Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides. PLoS Pathog (2012) 1.11
Aberrant host immune response induced by highly virulent PRRSV identified by digital gene expression tag profiling. BMC Genomics (2010) 1.11
Feasibility of routine HIV testing among TB patients through a voluntary counselling and testing centre. Int J Tuberc Lung Dis (2007) 1.11
Hypoxic and hypercapnic ventilatory responses in awake children with congenital central hypoventilation syndrome. Am Rev Respir Dis (1989) 1.10